Amylyx Pharmaceuticals, Inc. Insider Trading Activity

Amylyx Pharmaceuticals granted Chief Medical Officer Camille L. Bedrosian equity awards on March 5, 2026.

Rhea-AI Filing Summary

Amylyx Pharmaceuticals granted Chief Medical Officer Camille L. Bedrosian equity awards on March 5, 2026. She received stock options for 143,985 shares at an exercise price of $0.00 and 95,990 shares of common stock as a restricted stock unit award.

The RSUs vest in four equal annual installments starting on March 1, 2027, subject to continued service. Twenty-five percent of the option vests on March 1, 2027, with the remainder vesting monthly over the following 36 months, also contingent on ongoing service.

Insider Trade Summary

Grant/Award: 239,975 shares

Grant/Award 2 txns

Insider Bedrosian Camille L

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	143,985	$0.00	$0.00
Grant/Award	Common Stock	95,990	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 143,985 contracts (Direct); Common Stock — 265,285 shares (Direct)

Footnotes (2)

1. F1. The reported transaction involves the Reporting Person's receipt of a restricted stock unit ("RSU") award. The RSUs shall vest in 4 equal annual installments, with the first installment vesting on March 1, 2027, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
2. F2. 25% of the shares subject to the option shall vest and become exercisable on March 1, 2027, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider equity awards did AMLX Chief Medical Officer Camille Bedrosian receive?

Camille Bedrosian received stock options for 143,985 shares at a $0.00 exercise price and 95,990 shares of common stock as a restricted stock unit award, all granted on March 5, 2026, as part of her compensation from Amylyx Pharmaceuticals.

How do the new Amylyx (AMLX) RSU awards for Camille Bedrosian vest?

The restricted stock units granted to Camille Bedrosian vest in four equal annual installments, with the first installment vesting on March 1, 2027. Each remaining annual tranche also requires her continued service with Amylyx Pharmaceuticals through the corresponding vesting dates to be earned.

What is the vesting schedule for Camille Bedrosian’s Amylyx stock options?

For Camille Bedrosian’s stock options, 25% of the 143,985-share grant vests and becomes exercisable on March 1, 2027. The remaining 75% vests in equal monthly installments over the next 36 months, conditioned on her continuous service to Amylyx Pharmaceuticals during that period.

Does the Amylyx (AMLX) Form 4 show Camille Bedrosian buying or selling shares?

The Form 4 reports equity awards granted to Camille Bedrosian, not open-market buying or selling. She acquired 95,990 restricted stock units and 143,985 stock options at a $0.00 exercise price as compensation, with future vesting tied to her continued service at the company.

What role does Camille Bedrosian hold at Amylyx Pharmaceuticals (AMLX)?

Camille L. Bedrosian serves as Chief Medical Officer at Amylyx Pharmaceuticals. The reported Form 4 details equity awards she received in that capacity, including restricted stock units and stock options that vest over multiple years, aligning part of her compensation with company performance and tenure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/09/2026 - 04:00 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bedrosian Camille L

(Last) (First) (Middle)

C/O AMYLYX PHARMACEUTICALS, INC.

55 CAMBRIDGE PARKWAY, SUITE 6W

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Amylyx Pharmaceuticals, Inc. [ AMLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/05/2026		A		95,990(1)	A	$0	265,285	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$14.1	03/05/2026		A		143,985		(2)	03/05/2036	Common Stock	143,985	$0	143,985	D

Explanation of Responses:

1. The reported transaction involves the Reporting Person's receipt of a restricted stock unit ("RSU") award. The RSUs shall vest in 4 equal annual installments, with the first installment vesting on March 1, 2027, subject to the Reporting Person's continued service to the Issuer through each such vesting date.

2. 25% of the shares subject to the option shall vest and become exercisable on March 1, 2027, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.

	/s/ Joshua B. Cohen, as Attorney in Fact	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.